What is the recommended vitamin D repletion and maintenance regimen for an older female patient with dementia who has a serum 25‑hydroxyvitamin D level of 12 ng/mL?

Vitamin D Supplementation for Deficiency in a Female Patient with Dementia

This patient requires immediate vitamin D repletion with ergocalciferol 50,000 IU weekly for 8-12 weeks, followed by maintenance therapy with cholecalciferol 800-1,000 IU daily, targeting serum levels >30 ng/mL (75 nmol/L). 1

Rationale for Supplementation

The prevalence of vitamin D deficiency is extremely high in older adults with cognitive disorders, with up to 87% of frail hospitalized elderly patients being deficient. 2, 3 International expert consensus strongly recommends measuring serum 25-hydroxyvitamin D in all patients with cognitive disorders and supplementing when deficient, given the high prevalence in this population. 2

Vitamin D supplementation should be part of the care management of older adults with dementia, despite the lack of well-conducted randomized trials specifically demonstrating cognitive benefit. 2 The recommendation is based on:

• General health benefits: Vitamin D deficiency affects multiple organ systems beyond the brain, including increased risk of hypertension, type 2 diabetes, vascular disease, osteoporosis, and falls—all of which worsen functional independence in dementia patients. 2

• Potential neuroprotective effects: Hypovitaminosis D is associated with accelerated cognitive decline, particularly in executive function and episodic memory domains. 4 Low vitamin D status increases dementia risk by 1.42-fold and Alzheimer's disease risk by 1.57-fold. 5

• Cerebrovascular protection: Vitamin D deficiency is associated with increased white matter hyperintensity volume, large vessel infarcts, and stroke risk—all of which contribute to cognitive decline. 6

Specific Repletion Protocol

Initial Correction Phase (8-12 weeks)

• Ergocalciferol 50,000 IU once weekly for severe deficiency (level <20 ng/mL). 1, 7
• Take with food to enhance absorption. 7

Maintenance Phase (ongoing)

• Cholecalciferol 800-1,000 IU daily after correction phase. 1
• Some evidence suggests >800 IU daily may provide additional benefit, with a five-fold reduction in Alzheimer's disease risk over 7 years. 8

Target Serum Level

• Minimum target: ≥30 ng/mL (75 nmol/L). 1, 8
• Optimal range: 60-70 ng/mL based on dose-response meta-analysis for dementia prevention. 8, 5

Monitoring

• Recheck serum 25-hydroxyvitamin D in 3-6 months after initiating therapy to confirm target attainment. 8

Critical Caveats and Pitfalls

What NOT to Do

• Avoid megadoses (≥500,000 IU annually): These increase the risk of falls and fractures rather than preventing them. 1, 9
• Do not use active vitamin D analogs (calcitriol, alfacalcidol) for nutritional deficiency—these are reserved for chronic kidney disease stage 5. 1
• Do not rely on vitamin D as the sole intervention for cognitive decline; it must be part of comprehensive dementia management. 8

Important Limitations

• Vitamin D supplementation is NOT recommended specifically to prevent or treat cognitive decline according to ESPEN guidelines, based on very low-quality evidence from clinical trials. 1, 9 The discrepancy exists because observational studies show strong associations between low vitamin D and dementia risk, but randomized trials have failed to demonstrate cognitive benefit from supplementation. 1

• Serum 25-hydroxyvitamin D should NOT be used as a diagnostic or prognostic biomarker for dementia due to lack of specificity—it is too common in older adults to be useful for screening or diagnosis. 2, 9

Potential Adjunctive Benefit

• Consider restoring vitamin D levels before initiating or as an adjunct to standard anti-dementia treatments. One 6-month trial showed that memantine plus vitamin D was superior to either alone, with a clinically significant 4-point gain on Mini-Mental State Examination. 2

Additional Considerations for This Patient

Given that vitamin D deficiency is associated with faster cognitive decline in executive function and episodic memory 4, and that deficiency may explain variability in dementia symptoms through effects on comorbidities 2, correction is particularly important in this patient. The temporal relationship from longitudinal studies confirms that vitamin D deficiency precedes cognitive decline, reducing concerns about reverse causality. 8

Cognitive improvements, particularly in executive function and processing speed, may be observed as early as 4 weeks after initiating supplementation. 8